EUVIMEDOpdag EUVIMED
Crossref

Fragment‐Based Design of Pseudo‐Natural Products, Synthesis, and Evaluation of Their HIV ‐1 Latency‐Reversing Properties

Solange A Tanyi iD, Donatus B Eni iD, Mohamed Abdelsalam iD, Mathieu J M Tjegbe iD, Matthias Schmidt iD, Roland N Ndip iD, Ian Tietjen iD, Wolfgang Sippl iD, Fidele Ntie-Kang iD

Chemical Biology & Drug Design · 2026-02 · 107 (2)

DOI: 10.1111/cbdd.70235 ↗

At a glance

Journal article in Chemical Biology & Drug Design, published online on 2026-02-17. Written by Solange A Tanyi and 8 co-authors. Institution: Center for Drug Discovery, Faculty of Science, University of Buea, Buea, Cameroon. Major MEDLINE topics: HIV-1, Histone Deacetylase Inhibitors, Virus Latency, Biological Products. Cited 3 times so far (Crossref); 47 references. Funded by: Gates Foundation, Bill and Melinda Gates Foundation, LifeArc.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The goal of this project is to design, synthesize, and test compounds that combine fragments derived from natural products (NPs) for their HIV‐1 latency‐reversal properties, particularly those that act by histone deacetylase inhibition. A fragment library was created by implementing the Retrosynthetic Combinatorial Analysis Procedure (RECAP) on a collection of NPs isolated from different regions in Africa. The top‐scoring docked fragments within the histone deacetylase (HDAC1) binding site were reconstructed to design and synthesize chemical scaffolds that have not been previously described as HDAC inhibitors. Synthesized compounds were then tested for the ability to reverse HIV latency in J‐Lat 10.6 cells and/or inhibit cellular histone deacetylases. The synthesized scaffolds include indole‐chalcones and aminobenzamides. Of fifty‐one synthesized compounds, compound S2‐13 was the most active with HIV latency reversal 20.2% ± 6.2% of J‐Lat 10.6 cells at 10 μg/mL (25.1 μM), which was comparable to the HIV latency‐reversing agent Prostratin. S2‐13 also inhibited HDAC activity with a half‐maximal inhibitory concentration (IC 50 ) of 17.0 μM. We demonstrate that the use of pseudo‐NPs can identify novel chemical scaffolds that can reverse HIV latency and inhibit HDACs in vitro.

Subjects

MeSH terms (MEDLINE)

HIV-1Histone Deacetylase InhibitorsVirus LatencyBiological ProductsDrug DesignAnti-HIV AgentsHumansHistone Deacetylase 1Binding SitesCell LineMolecular Docking SimulationIndolesChalcones

Author keywords

HIV‐1antiviralcompoundshistone deacetylaselatency reversalpseudo‐natural products

Substances

Histone Deacetylase InhibitorsBiological ProductsHistone Deacetylase 1Anti-HIV AgentsIndolesChalcones

Authors and institutions

  • Center for Drug Discovery, Faculty of Science, University of Buea, Buea, Cameroon.
  • Department of Chemistry, Faculty of Science, University of Buea, Buea, Cameroon.
  • Department of Chemistry, Higher Teachers' Training College, University of Buea, Buea, Cameroon.
  • Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, Halle (Saale), Germany.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
  • The Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.

ORCID profiles: Solange A Tanyi, Donatus B Eni, Mohamed Abdelsalam, Mathieu J M Tjegbe, Matthias Schmidt, Roland N Ndip, Ian Tietjen, Wolfgang Sippl, Fidele Ntie-Kang

Funding

  • Gates Foundation
  • Bill and Melinda Gates Foundation
  • LifeArc
  • Alexander von Humboldt-Stiftung

Cite

APA

Tanyi, S. A., Eni, D. B., Abdelsalam, M., Tjegbe, M. J. M., Schmidt, M., Ndip, R. N., Tietjen, I., Sippl, W., & Ntie-Kang, F. (2026). Fragment‐Based Design of Pseudo‐Natural Products, Synthesis, and Evaluation of Their HIV ‐1 Latency‐Reversing Properties. Chemical Biology & Drug Design, 107(2). https://doi.org/10.1111/cbdd.70235

Vancouver

Tanyi SA, Eni DB, Abdelsalam M, Tjegbe MJM, Schmidt M, Ndip RN, et al. Fragment‐Based Design of Pseudo‐Natural Products, Synthesis, and Evaluation of Their HIV ‐1 Latency‐Reversing Properties. Chemical Biology & Drug Design. 2026;107(2). doi:10.1111/cbdd.70235

BibTeX
@article{Tanyi2026,
  author = {Tanyi, Solange A and Eni, Donatus B and Abdelsalam, Mohamed and Tjegbe, Mathieu J M and Schmidt, Matthias and Ndip, Roland N and Tietjen, Ian and Sippl, Wolfgang and Ntie-Kang, Fidele},
  title = {Fragment‐Based Design of Pseudo‐Natural Products, Synthesis, and Evaluation of Their HIV ‐1 Latency‐Reversing Properties},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {107},
  number = {2},
  doi = {10.1111/cbdd.70235}
}
Start for free →